Article Details
Retrieved on: 2024-09-09 20:41:00
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article explains how the recent Supreme Court decision in Loper Bright Enterprises v. Raimondo overturns the Chevron doctrine, affecting regulatory authority over lab-developed tests (LDTs). This shift impacts MedTech regulation as courts no longer defer to FDA interpretations, potentially favoring industry challenges to FDA rules.
Article found on: medtech.citeline.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here